WaveMan
WaveMan · Company
SION · Sionna Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SION Sionna Therapeutics (SION) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002036042
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
91
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $62.6K priced

What the filings say about SION

Insiders, 180 days
-$67.3M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$21.8M
1 notice

Sionna Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Sionna Therapeutics, Inc. insiders sold a net $67.3M of stock across 168 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-09-21 SECtraded 2026-09-17
3,415,011
$21.6M
-40.2%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (2 buys, 24 sales), the last on Nov 19, 2025.
  • The trade is 98.1% of the 3,482,612 shares held after it.
  • No other insider sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. sold about $21.6M of SION on Sep 17, 2026, the largest insider sale at the company on our record; 91 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-09-21 SECtraded 2026-09-17
33,800
$252.1K
-40.2%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (2 buys, 24 sales), the last on Nov 19, 2025.
  • The trade is 1.0% of the 3,448,812 shares held after it.
  • No other insider sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. sold about $252.1K of SION on Sep 17, 2026; 91 funds added in the latest 13F quarter.
ORBIMED ADVISORS LLC
Director
SELL
2026-07-09 SECtraded 2026-07-07
85,918
$3.9M
-92.1%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 30, 2026.
  • The trade is 3.5% of the 2,469,959 shares held after it.
  • 2 other insiders sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ORBIMED ADVISORS LLC sold about $3.9M of SION on Jul 7, 2026; 2 other insiders sold within 30 days and 91 funds added in the latest 13F quarter.
Thompson Peter A.
Director
SELL
2026-07-09 SECtraded 2026-07-07
85,918
$3.9M
-92.1%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (1 buy, 19 sales), the last on Jun 30, 2026.
  • The trade is 3.5% of the 2,469,959 shares held after it.
  • 2 other insiders sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thompson Peter A. sold about $3.9M of SION on Jul 7, 2026; 2 other insiders sold within 30 days and 91 funds added in the latest 13F quarter.
Fitzpatrick Jennifer
Chief Legal Officer
SELL
2026-07-07 SECtraded 2026-07-06
10,250
$446.9K
-91.8%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 5, 2026.
  • 2 other insiders sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Fitzpatrick Jennifer sold about $446.9K of SION on Jul 6, 2026; 2 other insiders sold within 30 days and 91 funds added in the latest 13F quarter.
168 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 163 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$67.3M over 180 days
-$21.8M over 90 days · -$21.8M of it by a 10%+ holder
below 96% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
91 funds bought in last quarter
more than 65% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.6% of the float short (float per yahoo 2026-10-26) · 2.3 days to cover · settled 2026-09-30
more than 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SION

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-90.7%12M
-91%-50%-9%+31%2025-102025-122026-022026-042026-062026-082026-10 2026-09-17 · RA CAPITAL MANAGEMENT, L.P. sold $21.6M2026-04-15 · Thompson Peter A. sold $10.5M2026-04-15 · ORBIMED ADVISORS LLC sold $10.5M2026-04-16 · Thompson Peter A. sold $10.3M2026-04-16 · ORBIMED ADVISORS LLC sold $10.3M2026-01-22 · WINKELRIED JON sold $10.0M2026-05-11 · Thompson Peter A. sold $8.5M2026-05-11 · ORBIMED ADVISORS LLC sold $8.5M2026-06-30 · ORBIMED ADVISORS LLC sold $5.3M2026-06-30 · Thompson Peter A. sold $5.3M2025-10-24 · RA Capital Nexus Fund III, L.P. sold $4.8M2025-10-24 · RA Capital Nexus Fund III, L.P. sold $4.3M2025-11-24 · ORBIMED ADVISORS LLC sold $4.2M2025-11-24 · Thompson Peter A. sold $4.2M2026-07-07 · ORBIMED ADVISORS LLC sold $3.9M2026-07-07 · Thompson Peter A. sold $3.9M2026-05-08 · Thompson Peter A. sold $2.7M2026-05-08 · ORBIMED ADVISORS LLC sold $2.7M2025-10-24 · RA Capital Nexus Fund III, L.P. sold $2.6M2026-04-17 · Thompson Peter A. sold $2.3M2026-04-17 · ORBIMED ADVISORS LLC sold $2.3M2026-05-07 · Thompson Peter A. sold $2.2M2026-05-07 · ORBIMED ADVISORS LLC sold $2.2M2026-04-14 · Thompson Peter A. sold $2.1M2026-04-14 · ORBIMED ADVISORS LLC sold $2.1M2025-12-24 · OrbiMed Capital GP VIII LLC sold $1.5M2025-12-24 · Thompson Peter A. sold $1.5M2026-02-03 · Thompson Peter A. sold $1.3M2026-02-03 · OrbiMed Capital GP VIII LLC sold $1.3M2025-10-28 · RA Capital Nexus Fund III, L.P. sold $1.2M2025-11-19 · RA CAPITAL MANAGEMENT, L.P. sold $747.5K2025-11-17 · RA CAPITAL MANAGEMENT, L.P. sold $720.1K2025-10-28 · RA Capital Nexus Fund III, L.P. sold $677.5K2025-11-17 · RA CAPITAL MANAGEMENT, L.P. sold $573.2K2025-11-19 · RA CAPITAL MANAGEMENT, L.P. sold $573.1K2025-10-24 · RA Capital Nexus Fund III, L.P. sold $557.6K2025-11-17 · RA CAPITAL MANAGEMENT, L.P. sold $552.1K2025-11-25 · ORBIMED ADVISORS LLC sold $530.3K2025-11-25 · Thompson Peter A. sold $530.3K2025-11-19 · RA CAPITAL MANAGEMENT, L.P. sold $485.2K2025-11-17 · RA CAPITAL MANAGEMENT, L.P. sold $467.4K2026-07-06 · Fitzpatrick Jennifer sold $446.9K2026-09-17 · RA Capital Healthcare Fund, L.P. filed to sell $21.8M2026-07-06 · JENNIFER FITZPATRICK filed to sell $450.9K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SION: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
9,905,045 sh
$435.7M
TPG GP A, LLC
6,494,962 sh
$285.7M
VIKING GLOBAL INVESTORS LP
3,195,181 sh
$140.6M
Atlas Venture Life Science Advisors, LLC
2,995,602 sh
$131.8M
ORBIMED ADVISORS LLC
2,555,877 sh
$112.4M

Congress trades in SION

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SION planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
RA Capital Healthcare Fund, L.P.
Filed 2026-09-17
$21.8M
JENNIFER FITZPATRICK
Filed 2026-07-06
$450.9K

SION mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
PGIM Jennison Health Sciences Fund
$27.9M position · as of 2026-05-29
2.0%
ALPS Medical Breakthroughs ETF
$2.0M position · as of 2026-05-31
1.2%
Eventide Healthcare & Life Sciences Fund
$20.9M position · as of 2026-06-30
1.2%
JPMorgan Small Cap Growth Fund
$23.1M position · as of 2026-06-30
0.9%
Virtus Biotech Clinical Trials Etf
$407.8K position · as of 2026-07-31
0.9%
AlphaCentric Life Sciences and Healthcare Fund
$213.9K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
0 active
What changed recently
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharm
2026-09-11 · Active Not Recruiting → Completed
Phase 2
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and
2026-09-11 · Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $67.3M sold by insiders over 180 days, 91 funds added last quarter, $21.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SION financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$76.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-32.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-30.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-35.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-46.8%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Operating income-$89.0M-$70.6M
Net income-$75.3M-$61.7M
EPS (diluted)-1.88-15.99
Operating cash flow-$66.3M-$52.8M
Cash$58.5M$37.8M
SEC XBRL, fiscal years, as known on 2026-10-27

SION Stock Sonar score 4/7 axes

Find similar shapesCompare

SION ranks highest on institutional and government (65th percentile) and profitability (64th), and lowest on insider conviction (1st), among Pharma & Biotech peers.

Profitability
64
Inputs
  • Return on equity-32.3% · 66 pct, sector of 545
  • Return on assets-30.7% · 60 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-35.5% · 65 pct, sector of 576
Insider conviction
1
Inputs
  • Net Form 4 buying (codes P and S), 180d-$67.3M · 3 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
65
Inputs
  • Funds adding, latest quarter91 · 65 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+18.6% · 17 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SION filings, in plain words

Are Sionna Therapeutics insiders buying or selling SION?

In the 180 days to 2026-10-27, Sionna Therapeutics insiders were net sellers, a net $67.3M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of SION?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $21.8M of stock; the latest, by RA Capital Healthcare Fund, L.P., was filed 2026-09-17.

Read the full summary

In the 180 days to 2026-10-27, Sionna Therapeutics insiders were net sellers of SION, a net $67.3M across purchases and sales reported on Form 4 by 4 sellers. None of the 15 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $21.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies